Emily Kobayashi (Gavi) outlined the transition to the Gavi 6.0 strategy during the 2025 CHIC Symposium. The intervention detailed the consolidation of multiple funding streams into a single holistic grant model and a unified cash envelope to enhance transparency and country sovereignty. Key policy shifts include the introduction of country vaccine budgets with financing ceilings […]
Topic: Gavi Support
Mises à jour sur l’élimination du cancer du col de l’utérus et le paysage de la vaccination contre le HPV: séance de questions-réponses
Emily Kobayashi (Responsable du programme PVH, Gavi) et des responsables du PEV (Guinée, Malawi, Cameroun, RDC) ont discuté de la mise en œuvre du modèle Gavi 6.0 lors du Symposium CHIC 2025. La session a précisé que la nouvelle subvention unifiée intègre les ressources de Gavi aux budgets nationaux et aux financements partenaires (ex. Banque […]
HPV vaccination in the context of upcoming shifts in Gavi’s grant model
Emily Kobayashi (Gavi) outlined the transition to the Gavi 6.0 strategy during the 2025 CHIC Symposium. The intervention detailed the consolidation of multiple funding streams into a single holistic grant model and a unified cash envelope to enhance transparency and country sovereignty. Key policy shifts include the introduction of country vaccine budgets with financing ceilings […]
Updates in Cervical Cancer Elimination and HPV Vaccination Landscape: Q&A Session
Emily Kobayashi (Head of HPV Program, Gavi) and regional EPI managers (Guinea, Malawi, Cameroon, DRC) addressed the operationalization of the Gavi 6.0 model at the 2025 CHIC Symposium. The session clarified that the new unified grant integrates Gavi resources with national budgets and partner funding (e.g., World Bank). Key concerns focused on the 4% co-financing […]
Gavi Investments
The Gavi session outlined its 2022 “must‑win” priority to scale up HPV vaccination, aiming to immunize 86 million girls by 2025. It detailed support for both Gavi‑eligible and middle‑income countries, including vaccine grants, operational funding, health‑system strengthening, and pooled procurement mechanisms. The presentation highlighted rapid progress post‑COVID, new multi‑age cohort campaigns, and upcoming introductions in […]
Gavi: Mécanisme de financement, financement de la vaccination de rattrapage pour les groupes d’âges diverses, assistance technique
Emily Kobayashi, responsable du programme vaccin HPV chez Gavi, a présenté les mécanismes de soutien de l’Alliance pour l’introduction et la revitalisation des programmes de vaccination en Afrique francophone. Elle a rappelé que le VPH est une priorité stratégique de Gavi depuis 2022, avec l’objectif de vacciner 86 millions de filles d’ici 2025. Le soutien […]
Gavi: Funding mechanism, Multi-age cohort catch-up financing, technical assistance
Emily Kobayashi, Head of the HPV Vaccine Programme at Gavi, presented the Alliance’s support mechanisms for introducing and revitalizing HPV vaccination programs in francophone Africa. She outlined Gavi’s “must-win” prioritization of HPV since 2022, aiming to vaccinate 86 million girls by 2025. Support includes vaccine introduction grants, operational cost subsidies for multi-age cohorts, co-financing arrangements, […]
Overview of Gavi’s support for HPV vaccination programs in low and middle income countries (LMICs)
HPV vaccine delivery in Gavi-supported countries relies mainly on school-based platforms, complemented by outreach to reach out-of-school adolescents. Microplanning and joint coordination between health and education sectors ensure accurate cohort targeting and smooth logistics. Community engagement—through parent meetings, religious leaders, and media—helps address stigma and hesitancy. Trained vaccinators and health workers manage administration and adverse […]
Overview of Gavi’s support for HPV vaccination programs in low and middle income countries (LMICs) – Q&A Session
The session explored gender equity in HPV vaccination, clarifying that current focus is on girls due to cervical cancer burden, with boys possibly included in future strategies. Participants discussed Bangladesh’s upcoming national rollout in 2023, building on prior pilot success. Questions addressed the long-term immunity of single- or two-dose regimens, with evidence showing durable protection […]